RenovaCare, Inc. (RCAR) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerRenovaCare, Inc. (RCAR) trades at $0.0001. RenovaCare, Inc. is a development-stage biotech company focused on autologous cellular therapies for medical and aesthetic applications. Their primary focus is the CellMist System and SkinGun technology for skin regeneration. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for RCAR: RCAR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
RenovaCare, Inc. (RCAR) Healthcare & Pipeline Overview
RenovaCare, Inc., operating in the biotechnology sector, is focused on developing and commercializing autologous cellular therapies, primarily the CellMist System and SkinGun technology, for skin regeneration. As a development-stage company, RenovaCare aims to address unmet needs in medical and aesthetic applications through innovative cell-based solutions.
What Is the Investment Thesis for RCAR?
RenovaCare, Inc. presents a high-risk, high-reward investment opportunity characteristic of development-stage biotechnology companies. The core value driver is the successful commercialization of the CellMist System and SkinGun technology. Key catalysts include positive clinical trial results demonstrating efficacy in burn treatment and wound healing. The company's strategic collaboration with StemCell Systems GmbH could accelerate development and expand the application of its technologies. However, the company faces significant risks, including regulatory hurdles, limited financial resources, and competition from established players in the regenerative medicine field. The small market capitalization and OTC listing introduce additional volatility and liquidity concerns. The company's success is contingent upon securing regulatory approvals, demonstrating clinical efficacy, and achieving market acceptance, all of which are subject to considerable uncertainty.
Based on FMP financials and quantitative analysis
RCAR Key Highlights
RenovaCare is a development-stage biotech company focused on autologous cellular therapies.
- The company's core technology includes the CellMist System and SkinGun for skin regeneration.
- RenovaCare has a strategic collaboration with StemCell Systems GmbH for stem cell research.
- The company operates with a small team of 1 employee, indicating a lean operational structure.
- RenovaCare trades on the OTC market, which can present liquidity and volatility considerations.
Who Are RCAR's Competitors?
RCAR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RCAR's Key Strengths?
Proprietary CellMist System and SkinGun technology.
- Autologous cell therapy minimizes immune rejection.
- Potential for improved outcomes in burn treatment and wound healing.
- Strategic collaboration with StemCell Systems GmbH.
What Are RCAR's Weaknesses?
Development-stage company with limited revenue.
- Small team and limited financial resources.
- Reliance on successful clinical trials and regulatory approvals.
- OTC listing introduces liquidity and volatility concerns.
What Are the Key Risks for RCAR?
Negative return on equity (-94.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and delays in obtaining approvals.
- Uncertainty surrounding clinical trial outcomes.
- Competition from established biotech and pharmaceutical companies.
- Limited financial resources and reliance on external funding.
- Risk of technological obsolescence.
What Are RCAR's Competitive Advantages?
- Proprietary CellMist System technology.
- Patents protecting its autologous cell therapy approach.
- Strategic collaboration with StemCell Systems GmbH.
- First-mover advantage in autologous skin regeneration.
What Does RCAR Do?
RenovaCare, Inc., formerly known as Janus Resources, Inc., was renamed in January 2014 to reflect its focus on regenerative medicine. The company is dedicated to the research, development, and commercialization of autologous cellular therapies. These therapies utilize a patient's own cells to regenerate tissues, primarily targeting medical and aesthetic applications. RenovaCare's core technology revolves around the CellMist System, a proprietary method for isolating and preparing skin cells for regenerative purposes. Complementing this system is the SkinGun, a device designed to deliver these cells to the treatment area. Based in Scottsdale, Arizona, RenovaCare operates with a small team, emphasizing strategic collaborations to advance its technology. A key partnership is with StemCell Systems GmbH, focusing on the isolation and spraying of self-donated stem cells for tissue and organ regeneration. RenovaCare's business model centers on developing and patenting its autologous cell therapies, with the long-term goal of commercializing these technologies for burn treatment, wound healing, and aesthetic procedures. The company's success hinges on navigating regulatory approvals, demonstrating clinical efficacy, and securing market adoption for its innovative cell-based solutions.
What Products and Services Does RCAR Offer?
- Develops CellMist System for isolating skin cells.
- Creates SkinGun device for delivering cells to treatment areas.
- Focuses on autologous cellular therapies.
- Targets medical applications like burn treatment.
- Aims for aesthetic applications such as scar revision.
- Collaborates with StemCell Systems GmbH for stem cell research.
How Does RCAR Make Money?
- Develops and patents autologous cell therapies.
- Seeks regulatory approvals for its technologies.
- Aims to commercialize technologies for burn treatment and wound healing.
- Potentially licenses technology to other companies.
What Industry Does RCAR Operate In?
RenovaCare operates within the regenerative medicine sector, a rapidly growing field focused on developing therapies to repair or replace damaged tissues and organs. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in cell biology and tissue engineering. The competitive landscape includes established biotech and pharmaceutical companies, as well as smaller, innovative players. RenovaCare aims to differentiate itself through its autologous cell therapy approach, which minimizes the risk of immune rejection. The company's success depends on navigating regulatory pathways, demonstrating clinical efficacy, and securing market share in a competitive environment.
Who Are RCAR's Key Customers?
- Hospitals and burn centers.
- Dermatologists and plastic surgeons.
- Patients requiring skin regeneration therapies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
RenovaCare, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Scottsdale, US. RCAR has traded publicly since 1996.
Insider Activity
12 transactions · 1 purchases, 0 sales, 11 other transactions · 6 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Financial Health
RenovaCare, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for RenovaCare, Inc. stands at -94.7%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 2.59 indicates the company holds enough short-term assets to cover its near-term obligations.
RCAR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
RCAR Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Thursday
· Dec 12, 2019
RCAR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RCAR.
Price Targets
Wall Street price target analysis for RCAR.
RCAR MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RCAR; grades run from A+ (80-100) to F (below 30).
Leadership: Harmel S. Rayat
Managing
Harmel S. Rayat serves as the managing person for RenovaCare, Inc. Information regarding Mr. Therefore, a comprehensive background profile cannot be constructed. However, his current role indicates leadership responsibility for the company's strategic direction and operations.
Track Record: Due to the limited information available, a detailed track record of Mr. Rayat's achievements and strategic decisions at RenovaCare, Inc. cannot be provided.
RCAR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that RenovaCare, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, and may be subject to greater regulatory scrutiny. Investing in OTC Other stocks carries significant risks due to the lack of transparency and potential for fraud or manipulation. Compared to NYSE or NASDAQ listings, OTC Other stocks have far less stringent listing requirements, resulting in a higher concentration of speculative and unproven companies.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volumes and liquidity.
- Greater price volatility and susceptibility to manipulation.
- Potential for delisting or suspension of trading.
- Higher risk of fraud or misrepresentation.
- Verify the company's registration and compliance with regulatory requirements.
- Obtain and review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal proceedings against the company.
- Company's focus on developing innovative autologous cell therapies.
- Strategic collaboration with StemCell Systems GmbH.
- Patents protecting its technology.
- Company's history of operating since its founding.
Common Questions About RCAR (Healthcare)
What are the main risks for RCAR?
RenovaCare, Inc. faces several significant risks inherent to development-stage biotech companies. These include the uncertainty of clinical trial outcomes, the potential for regulatory delays or rejection, competition from established players with greater resources, the need for substantial capital to fund research and development, and the risk of technological obsolescence.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Development-stage company with inherent uncertainties.